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LETTERS TO THE EDITOR
cently, we also demonstrated an up-regulation of uPARRelease of urokinase in tubular lesions associated to nephrotoxic nephritis in
the rat [4]. These results suggest that uPAR may play aplasminogen activator role in the pathogenesis of acute renal failure related to
acute tubular necrosis, either by focalizing uPA activityreceptor during urosepsis at the cell surface and promoting cell detachment from
the basement membrane, or by facilitating cell migrationand endotoxemia and recovery of tubular integrity. Experimental models
of acute tubular necrosis in uPAR knockout animals
would be helpful to determine if uPAR plays a patho-To the Editor: In the June 2001 issue of Kidney Inter-
genic role and whether it is deleterious or beneficial fornational, Florquin et al clearly show a strong and early
the kidney.upregulation of urokinase plasminogen activator recep-
tor (uPAR) in renal tubular epithelial cells during pyelo- Eric Rondeau
nephritis and an increase in both blood and urine levels Paris, France
of soluble uPAR during endotoxemia [1]. The authors
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quoted only one study about uPAR expression in the Tenon, 4 Rue de la Chine, Paris 75020, France.
E-mail: eric.rondeau@tnn.ap-hop-paris.frkidney that indicated that uPAR was found in all seg-
ments of the tubular epithelium in normal renal tissue
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transporters that lead to hypokalemia, volume depletion,Reduced content of  subunit as well as activation of the renin-angiotensin-aldosterone
system. In addition, patients with Bartter and Gitelmanof Gq protein content in syndromes present with normotension/hypotension, re-
duced peripheral resistance, and hyporesponsiveness tomonocytes of Bartter and pressors [1]. We recently provided a mechanistic expla-
nation for the decreased vascular reactivity characteristicGitelman syndromes: of Bartter and Gitelman syndromes by demonstrating
that there is a defective coupling of the agonist receptorRelationship with vascular to phospholipase C, at the level of the G subunit of the
Gq-binding protein. Protein kinase C activity is thereforehyporeactivity reduced, thereby inducing vascular hyporeactivity [2].
As the reduced expression of the Gq was based on
mRNA level [2], a direct demonstration of a correspon-
To the Editor: The clinical picture of Bartter and Gi- dent decrease in the abundance of Gq protein was
telman syndromes reflects functional defects in kidney required to further strengthen the existence of a defect
in the intracellular biochemical sequence of events that
leads to vascular hyporeactivity in Bartter and Gitelman
syndromes [3]. 2002 by the International Society of Nephrology
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syndromes had significantly reduced levels of Gq pro-
tein: 60  12 vs. 107  8 densitometric units; P  0.001
(Student t test).
The decrease in the abundance of Gq protein
strengthens the defect in the intracellular signaling that
reduces vascular reactivity of Bartter and Gitelman syn-
dromes. The next step will be to establish whether theFig. 1. Western blot of Gq protein expression in monocytes of healthy
controls (lanes 1 and 5) and of patients with Bartter and Gitelman reduction of Gq is a result of decreased production or
syndromes (lanes 2, 3, and 4). increased degradation, as well as to evaluate the molecu-
lar basis for these changes.
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function at baseline [2]. Interestingly, gemfibrozil wasPeroxisome proliferator-
devoid of this side effect [2]. A recent prospective study
in hyperlipemic patients with normal renal function con-activated receptors (PPARs):
firmed that fenofibrate, but not gemfibrozil, induced a
significant rise of serum creatinine level [3]. Of note,Novel therapeutic targets in
hyperhomocysteinemia was associated with fenofibrate-
induced increase in creatinine level [3].renal disease
On pathophysiological ground, the activation of PPAR
results in a down-regulation of the expression of cyclo-
To the Editor: In their excellent review on peroxisome oxygenase 2 (COX-2) and a reduction in the production
proliferator-activated receptors (PPARs), Dr. Guan and of vasodilatory prostaglandins [4]. These events may ob-
Dr. Breyer indicate that fibrates bind to and activate viously account for fibrate nephrotoxicity.
PPAR, but they do not mention any renal adverse event How should these data influence the nephrologist’s
associated with the modulation of PPAR activity [1]. We practice? First, we believe that fenofibrate, bezafibrate,
would like to emphasize the fact that fibrates may lead and ciprofibrate should not be prescribed to patients
to renal dysfunction. Indeed, an analysis of 27 patients with renal dysfunction. Second, hyperhomocysteinemia
from our institution who developed an impairment of may counteract the benefits expected from the lipid-
renal function during fibrate therapy and a literature lowering action of these fibrates. This is consistent with
review of 24 papers that reported data on 2676 patients trials showing that gemfibrozil is the only fibrate that
taking fibrates lead us to conclude that therapy with allowed for significant reductions of cardiac events in
fenofibrate, bezafibrate, and ciprofibrate may induce re- both primary and secondary prevention trials.
nal dysfunction [2]. This side effect was observed in pa-
tients with either native kidneys or kidney transplants Nilufer Broeders and Daniel Abramowicz
Brussels, Belgiumand among those with either normal or impaired renal
